Biology subjects

Gallucci, L.

Publications and source records attributed to Gallucci, L..

5 recordsLinked to original sources

bioRxiv2026

FDXR Upregulation by p63/p73 is a Prognostic and Therapeutic Marker of HTLV-1-Associated Adult T Cell Leukemia/Lymphoma

Infection with human T-lymphotropic virus 1 (HTLV-1) can lead to severe diseases, including adult T-cell leukemia/lymphoma (ATL), for which current therapies are inadequate. HTLV-1 persists chronically through integration of its genome into host DNA and expansion of infected clones via cellular proliferation. Selective elimination of infected cells is the ideal treatment goal but requires identifying cellular markers dysregulated by HTLV-1 that can be exploited therapeutically. Combining metabolomics and proteomics analyses, we identified increased expression of the mitochondrial enzyme ferredoxin reductase (FDXR) as a hallmark of HTLV-1-infected cells. In patient cells, FDXR upregulation mirrored disease severity, was enriched in proliferating tumour cells and predicted worse ATL prognosis. Mechanistically, FDXR upregulation was directly driven by the transactivating isoforms of two p53 family members, TAp63 and TAp73. In silico drug susceptibility predictions, followed by targeted cytotoxicity, proliferation and Drug-Seq assays demonstrated that FDXR upregulation is associated with increased sensitivity of ATL cells to repurposed chemotherapeutic agents, particularly fluorouracil. Overall, our findings establish FDXR as a novel biomarker of HTLV-1-associated disease progression and ATL prognosis, elucidate its upstream molecular regulation, and highlight its predictive potential for chemotherapeutic sensitivity of ATL cells.

microbiology↗

bioRxiv2025

Nitrification in a seagrass-sponge association

AO_SCPLOWBSTRACTC_SCPLOWIn the Mediterranean Sea, the demosponge Chondrilla nucula can occur in close association with the native seagrass Posidonia oceanica. C. nucula harbors a diverse and abundant microbial community, including potential nitrifiers. Thus, the sponge may contribute to the nitrogen (N) demand of the seagrass holobiont. In this study, we investigated potential nitrification rates (PNR) and inorganic N fluxes within this association at a site where C. nucula covered 18 {+/-} 3 % of the seagrass meadow area, during plant growth (spring) and senescence (autumn). Using incubation experiments with 15N-labeled ammonium, we measured PNR and inorganic N of the seagrass-sponge association, and of sponge and seagrass independently, under light and dark conditions. We supplemented these experiments with 16s rRNA gene amplicon sequencing to characterize the microbial community of the sponge. PNR was exclusively measured when the sponge was present (alone or in association with the seagrass). PNR was highest in the dark and when C. nucula was associated with the seagrass, ranging from 21 {+/-} 7 to 267 {+/-} 33 nmol N g DW-1 h-1 in spring and autumn, respectively. Sponge-mediated PNR can support 8% of the N demand of the P. oceanica holobiont during growth and 47 % during senescence. We identified key nitrifying bacterial and archaeal groups as members of the sponges microbial community. While C. nucula released inorganic N, potentially sustaining the seagrass, it benefitted from dissolved organic carbon released by P. oceanica. These results suggest that the interaction between C. nucula and P. oceanica is mutually beneficial, ultimately supporting and stabilizing the seagrass ecosystem.

ecology↗

bioRxiv2024

Control without cause: How covariate control biases our insights into brain architecture and pathology

Inferential analysis of normal or pathological brain imaging data - as in brain mapping or the identification of neurological imaging markers - is often controlled for secondary variables. However, a rationale for covariate control is rarely given and formal criteria to identify appropriate covariates in such complex data are lacking. We investigated the impact and adequacy of covariate control in large-scale imaging data using the example of stroke lesion-deficit mapping. In 183 stroke patients, we evaluated control for age, sex, hypertension, or lesion volume when mapping real or simulated deficits. We found that the impact of covariate control varies and can be strong, but it does not necessarily improve the precision of results. Instead, it systematically shifts results towards the inversed associations between imaging features and the covariate. This effect of covariate control can bias results and, as shown in another experiment, can even create effects out of nothing. The widespread use of covariate control in the statistical analysis of clinical brain imaging data - and, likely, other biological high-dimensional data as well - may not generally improve statistical results, but it may just change them. Therefore, covariate control constitutes a problematic degree of freedom in the analysis of brain imaging data and may often not be justified at all.

neuroscience↗

bioRxiv2023

Broad-spectrum antiviral activity of clinically approved CYP3A inhibitors against pathogenic human coronaviruses in vitro

Coronaviruses pose a permanent risk of outbreaks, with three highly pathogenic species and strains (SARS-CoV, MERS-CoV, SARS-CoV-2) having emerged in the last twenty years. Limited antiviral therapies are currently available and their efficacy in randomized clinical trials enrolling SARS-CoV-2 patients has not been consistent, highlighting the need for more potent treatments. We previously showed that cobicistat, a clinically approved inhibitor of Cytochrome P450-3A (CYP3A), has direct antiviral activity against early circulating SARS-CoV-2 strains in vitro and in Syrian hamsters. Cobicistat is a derivative of ritonavir, which is co-administered as pharmacoenhancer with the SARS-CoV-2 protease inhibitor nirmatrelvir, to inhibit its metabolization by CPY3A and preserve its antiviral efficacy. Here, we used automated imaging and analysis for a screening and parallel comparison of the anti-coronavirus effects of cobicistat and ritonavir. Our data show that both drugs display antiviral activity at low micromolar concentrations against multiple SARS-CoV-2 variants in vitro, including epidemiologically relevant Omicron subvariants. Despite their close structural similarity, we found that cobicistat is more potent than ritonavir, as shown by significantly lower EC50 values in monotherapy and higher levels of viral suppression when used in combination with nirmatrelvir. Finally, we show that the antiviral activity of both cobicistat and ritonavir is maintained against other human coronaviruses, including HCoV-229E and the highly pathogenic MERS-CoV. Overall, our results demonstrate that cobicistat has more potent anti-coronavirus activity than ritonavir and suggest that dose adjustments could pave the way to the use of both drugs as broad-spectrum antivirals against highly pathogenic human coronaviruses.

microbiology↗

bioRxiv2021

The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication

Combinations of direct-acting antivirals are needed to minimize drug-resistance mutations and stably suppress replication of RNA viruses. Currently, there are limited therapeutic options against the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) and testing of a number of drug regimens has led to conflicting results. Here we show that cobicistat, which is an-FDA approved drug-booster that blocks the activity of the drug metabolizing proteins Cytochrome P450-3As (CYP3As) and P-glycoprotein (P-gp), inhibits SARS-CoV-2 replication. Cell-to-cell membrane fusion assays indicated that the antiviral effect of cobicistat is exerted through inhibition of spike protein-mediated membrane fusion. In line with this, incubation with low micromolar concentrations of cobicistat decreased viral replication in three different cell lines including cells of lung and gut origin. When cobicistat was used in combination with the putative CYP3A target and nucleoside analog remdesivir, a synergistic effect on the inhibition of viral replication was observed in cell lines and in a primary human colon organoid. The cobicistat/remdesivir combination was able to potently abate viral replication to levels comparable to mock-infected cells leading to an almost complete rescue of infected cell viability. These data highlight cobicistat as a therapeutic candidate for treating SARS-CoV-2 infection and as a potential building block of combination therapies for COVID-19.

microbiology↗